期刊文献+

某院生物等效性试验健康受试者筛选失败原因分析 被引量:2

Analysis of the Reasons for the Failure of Screening Healthy Subjects in the Bioequivalence Test in the Hospital and Discussion of Some Common Problems
原文传递
导出
摘要 目的对某院开展的生物等效性试验中健康受试者筛选情况进行分析,探讨受试者筛选失败的原因。方法总结分析2019年1月~2020年5月在该院开展的8项生物等效性试验健康受试者临床资料。结果筛败因素包括生命体征、实验室检查、BMI、心电图检查等,其中占比最大的是实验室检查不合格(47.43%),其次为生命体征异常(14.54%)和BMI不合格(9.40%)。结论实验室检查是造成筛选失败的最主要原因,生命体征和依从性也严重影响筛选的成败。研究者应加强重视筛选过程中出现的各种问题,以提高筛选成功率。 OBJECTIVE To analyze the screening of healthy volunteers and explore the causes of screening failure in the bioequivalence test in our hospital.METHODS Clinical subject data of the healthy volunteers in 8 bioequivalence test carried out in our hospital form January 2019 to May 2020 were analyzed.RESULTS The factors for the screening failure included vital signs,laboratory examination,BMI,electrocardiograms and so on.Unqualified laboratory examination(47.43%)was accounted for the largest proportion,followed by abnormal vital signs(14.54%)and BMI(9.40%).CONCLUSION Laboratory examination is the main cause of screening failure,vital signs and compliance also seriously affect the success of screening.The researchers should attach importance to the issues in screening to improve the success rate.
作者 陈丽丽 潘芸芸 叶嘉俊 沈勇刚 CHEN Lili;PAN Yunyun;YE Jiajun;SHEN Yonggan(The First Affiliated Hospital of Guangdong Pharmaceutical University,Guangzhou,Guangdong 510080,China)
出处 《今日药学》 CAS 2022年第4期318-320,共3页 Pharmacy Today
关键词 临床试验 生物等效性试验 健康受试者筛选 clinical trials bioequivalence study screening of healthy volunteers
  • 相关文献

参考文献13

二级参考文献104

  • 1卫生部新闻办公室.卫生部公布第四次国家卫生服务调查主要结果[R].北京:卫生部,2009-02-27.
  • 2Guindon GE, Boisclair D. Past, current and future trends in tobacco use. Health, Nutrition and Population ( NHP ) discussion paper. Economics of tobacco control paper No. 6 [ R~. Washington DC : World Bank,2003.
  • 3Lucas C, Martin J. Smoking and drug interactions [ J ]. Australian Prescriber,2013,36 (3) ~ 102-104.
  • 4Ellingrod VL. Drug interactions with tobacco smoke: Implications for patient care[ J]. Current Psychiatry ,2013,12 ( 1 ) : 12-16.
  • 5Rouhos A, Raaska K. Smoking and drug interactions [ J ]. Duodecim; l~i~iketieteellinen aikakauskirja,2012,128 (10) : 1073-1080.
  • 6Plowchalk DR, Yeo KR. Prediction of drug clearance in a smoking population : modeling the impact of variable cigarette consumption on the induction of CYP1A2 [ J]. Eur J Clin Pharmacol, 2012, 68 (6) ; 951-960.
  • 7Zhou SF, Yang LP, Zhou ZW, et al. Insights into the substrate specificity, inhibitom, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1 A2 i J ]. The AAPS journal, 2009, 11 (3) :481-494.
  • 8Zevin S, Benowitz NL Drug interactions with tobacco smoking [ J ]. Clin Pharmacokinet, 1999,36 ( 6 ) :425-438.
  • 9Keizer I, Descloux V, Eytan A. Variations in smoking after admission to psychiatric inpatient units and impact of a partial smoking ban on smoking and on smoking-related perceptions [ J ]. Int J Soc Psychiatry, 2009,55(2) :109-123.
  • 10Wahawisan J, Kolluru S, Nguyen T, et al. Methadone Toxicity Due to Smoking Cessation--A Case Report on the Drug-Drug Interaction Involving Cytochrome 17450 Isoenzyme 1A2 [ J]. Ann Pharmaeother, 2011,45(6) :e34-e34.

共引文献125

同被引文献21

引证文献2

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部